At the extraordinary general meeting in ADDvise Group AB (publ) ("ADDvise") held today on 16 February 2026, Mia Tomczak and Richard Jernberg were elected as new board members of the company. The resolution means that the board of directors shall consist of Fredrik Celsing (chairman), Mia Tomczak, and Richard Jernberg for the period until the end of the next annual general meeting.
The general meeting was held at the request of Amplex AB that through its public offer and acquisitions outside the offer controls more than 90 per cent of the shares in ADDvise.
As previously communicated, the shares and warrants in ADDvise will be delisted from Nasdaq First North Premier Growth Market. The last day of trading will be tomorrow, 17 February 2026.
For more information, please contact:
Staffan Torstensson, CEO
Phone: +46 704 33 20 19
Email: staffan.torstensson@addvisegroup.se
About ADDvise Group
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 1.6 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.
